Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy

Intratumor heterogeneity leads to different responses to targeted therapies, even within patients whose tumors harbor identical driver oncogenes. This study examined clinical outcomes according to a patient-derived cell (PDC)-based drug sensitivity test in lung cancer patients treated with targeted...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2024-02, Vol.16 (4), p.778
Hauptverfasser:	Kim, Sunshin, Lee, Youngjoo, Song, Bo Ram, Sim, Hanna, Kang, Eun Hye, Hwang, Mihwa, Yu, Namhee, Hong, Sehwa, Park, Charny, Ahn, Beung-Chul, Lim, Eun Jin, Hwang, Kum Hui, Park, Seog-Yun, Choi, Jin-Ho, Lee, Geon Kook, Han, Ji-Youn
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents Cancer Cancer therapies Cells Chemotherapy Data collection Development and progression Drug screening Drugs Epidermal growth factor receptors Genomics Lung cancer Lung cancer, Non-small cell Medical research Medicine, Experimental Mutation Non-small cell lung carcinoma Oncogenes Patient outcomes Patients Precision medicine Prognosis Sensitivity analysis Small cell lung carcinoma Software Tumors Variance analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!